American journal of clinical pathology最新文献

{"title":"Comprehensive characterization of nodal peripheral T-cell lymphoma, not otherwise specified: A report of the 2023 SH/EA4HP lymphoma workshop.","authors":"Catalina Amador, Alyssa Bouska, Rauf Shah, Javeed Iqbal, Francisco Vega","doi":"10.1093/ajcp/aqaf025","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf025","url":null,"abstract":"<p><strong>Objective: </strong>To summarize the conclusions of the 2023 Society for Hematopathology/European Association for Hematopathology Workshop in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS).</p><p><strong>Methods: </strong>There were 36 cases with a submitted diagnosis of PTCL reviewed in Session 2.</p><p><strong>Results: </strong>The cases were classified based on submitted data and additional studies conducted during the workshop, including nodal PTCL with γδ immunophenotype (n = 5), PTCL-NOS subclassified into PTCL-TBX21 (n = 8) and PTCL-GATA3 (n = 8) molecular subtypes, PTCL-NOS expressing CD30 (n = 2), PTCL arising from an underlying low-grade T-cell lymphoproliferative disorder (n = 2), and nodal involvement by primary cutaneous T-cell lymphoma (n = 5). Additionally, we reviewed 5 cases of T-cell lymphoma with lymphoepithelioid features, including 2 cases that do not meet the current criteria for PTCL-NOS, with 1 included in PTCL-TBX21 and 1 in PTCL γδ described above. Three cases remain unclassified. We highlight the diagnostic challenges of PTCL-NOS, emphasizing the importance of performing a comprehensive panel of immunomarkers and molecular studies to establish the diagnosis and address the heterogeneity of these lymphomas. We identify rare cases of nodal γδ PTCL-NOS with a unique immunophenotype and TP53 mutations. We also discuss the features of PTCL-GATA3 and PTCL-TBX21, including enrichment for cytotoxic markers in PTCL-TBX21 and aberrant B-cell marker expression in a subset of PTCL-GATA3 cases. The differential diagnosis of PTCL-NOS cases expressing, as well as those with lymphoepithelioid features, is briefly discussed. The importance of access to clinical history and staging is emphasized, as demonstrated by cases of nodal involvement by primary cutaneous T-cell lymphomas and cases that have progressed from low-grade lymphoproliferative disorders.</p><p><strong>Conclusions: </strong>Peripheral T-cell lymphoma, not otherwise specified is heterogeneous with distinct emerging subgroups. The diagnosis is complex and requires a comprehensive approach.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"65-75"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The expanding spectrum of T-cell lymphomas with follicular helper T-cell phenotype and implications for differential diagnoses: A report of the 2023 SH/EA4HP Lymphoma Workshop.","authors":"Ahmet Dogan, Ozgur Can Eren, Laurence de Leval","doi":"10.1093/ajcp/aqaf040","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf040","url":null,"abstract":"<p><strong>Objectives: </strong>The 2023 Society of Hematopathology/European Association for Haematopathology Workshop on Progress in Peripheral T- and NK-Cell Lymphomas addressed challenges in diagnosis, biomarkers, and molecular pathogenesis.</p><p><strong>Methods: </strong>Session 1 of the workshop focused on T-follicular helper (TFH) lymphomas and related entities. Sixty-one cases were submitted, and their histology, phenotype, and genetics were reviewed.</p><p><strong>Results: </strong>The panelists confirmed 46 cases as TFH lymphomas, more commonly angioimmunoblastic type than follicular or not otherwise specified. A small subset of patients were young adults. Expected immunophenotypic profile, with expression of pan T-cell markers and TFH-specific markers with subtle differences between the histologic subtypes was observed. Genetic analyses revealed classic genetic alterations associated with these tumors, including frequent mutations in epigenetic modifiers (eg, TET2, DNMT3A, and IDH2) and RHOA. A broad spectrum of clonal B-cell proliferations was associated with TFH lymphomas, including polymorphic proliferations to large B-cell lymphoma-like expansions, often associated with Epstein-Barr virus. The remaining 15 cases were reclassified with alternative diagnoses, underscoring the diagnostic challenges and complexity in distinguishing TFH lymphomas from other entities.</p><p><strong>Conclusions: </strong>The cases highlighted the clinical and biological heterogeneity and complexity of TFH lymphomas and provided a framework for pathology workup and diagnosis as well as future research.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":"164 1","pages":"85-109"},"PeriodicalIF":2.3,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resident in-service examination first-year trainee survey results: Comparison of US and international medical graduates' perceived preparedness for pathology residency.","authors":"Alisha M Maltos, Jodi Gedallovich, Rebecca K Miller-Kuhlmann, Kimberly W Sanford, Ali Brown, Jay Wagner, Kelly Ernst","doi":"10.1093/ajcp/aqaf065","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf065","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the academic backgrounds and medical school pathology exposure among first-year pathology residents, comparing graduates from the United States and international medical schools.</p><p><strong>Methods: </strong>A survey was administered as part of the Resident In-Service Examination First, offered by the American Society for Clinical Pathology, which assessed academic background, preparedness for residency, and prior exposure to pathology education. Associations between undergraduate pathology exposure, timing of residency selection, reported preparedness, and examination performance were analyzed.</p><p><strong>Results: </strong>Of the 417 residents who completed the survey, 39.3% had graduated from international medical institutions. International medical graduates reported higher rates of medical school curricula that included required pathology rotations (33.5% vs 3.6%, P = .001) and greater perceived preparedness for anatomic pathology residency (28.7% vs 15.8%, P = .002), with no significant difference in examination performance. Additionally, 22.5% of US medical student respondents selected pathology before medical school, compared to only 10.4% of international medical graduates (P = .002).</p><p><strong>Conclusions: </strong>This study highlights differences in educational exposure and perceived preparedness for pathology residency between US and international medical graduates, with international medical graduates reporting more preresidency exposure to pathology and higher perceived confidence at the start of residency. These findings suggest potential areas for curricular improvement in US medical schools to enhance pathology exposure.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative analysis of the significance of depth of invasion and tumor thickness in the staging of oral cavity squamous cell carcinoma.","authors":"Maria Faraz, Neharika Shrestha, Syed M Gilani","doi":"10.1093/ajcp/aqaf066","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf066","url":null,"abstract":"<p><strong>Objective: </strong>According to the American Joint Committee on Cancer (AJCC) 8th edition, tumor depth of invasion is one of the essential parameters required for the staging of oral cavity squamous cell carcinoma (OSCC). We conducted this study to overview our diagnostic challenges and share our institutional experiences related to the measurement of depth of invasion.</p><p><strong>Methods: </strong>We selected 90 OSCC cases between 2017 and 2023. The depth of invasion and tumor thickness were remeasured in each case, and the tumor stage was assigned according to the AJCC 8th edition criteria.</p><p><strong>Results: </strong>We found that 84 of 90 (93.3%) had the same tumor stage, whether defined by tumor thickness or depth of invasion. Overall, the difference between tumor thickness and depth of invasion ranged from 0 to 3 mm. In only 6 of the 90 (6.7%) cases was the tumor stage changed based on tumor thickness. Of these 6 cases, 4 were upgraded from T1 to T2, while the remaining 2 were upgraded from T2 to T3.</p><p><strong>Conclusions: </strong>We observed that in 93.3% of our OSCC cases, tumor stage remained the same with either depth of invasion or tumor thickness, while 6.7% were upstaged based on tumor thickness. Based on the study observations, tumor thickness appears to be more straightforward to measure than depth of invasion. In contrast, depth of invasion measurement requires certain prerequisites and can pose diagnostic challenges. Additional studies with larger cohorts are needed to compare tumor thickness with depth of invasion findings.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimized strategy to mitigate daratumumab interference in blood bank testing: Reducing cost and time.","authors":"Tom Yu, Antonio Insigne, Walia Anushka, Elena Nedelcu","doi":"10.1093/ajcp/aqaf060","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf060","url":null,"abstract":"<p><strong>Objective: </strong>Drug interference with pretransfusion testing in patients with multiple myeloma (MM) treated with daratumumab (DARA) is well recognized. Current guidelines recommend that these patients should have a red blood cell (RBC) phenotype or genotype before DARA initiation; however, there are no other standards for pretransfusion testing. While prior publications report mitigation strategies and low RBC alloimmunization risk, they do not propose a cost-effective strategy for pretransfusion testing. This study aims to assess the RBC alloimmunization risk in patients treated with DARA and propose a cost-effective algorithm for pretransfusion testing.</p><p><strong>Methods: </strong>This is a retrospective study of patients treated with DARA and receiving RBC transfusions over 9.4 years (October 1, 2015, to January 30, 2025). Demographic data; a complete serologic profile, including blood typing, antibody screen (Ab screen), and antibody identification (Ab ID); RBC phenotype/genotype; and crossmatch data were collected for each patient. The clinically significant antibody formation incidence was recorded pre- and post-DARA and compared with a control group, with statistical significance defined as P < .05. The mitigation strategy initially used for pretransfusion testing and its optimized version are described along with their cost.</p><p><strong>Results: </strong>Of the 850 patients with MM on DARA therapy who were identified, 172 (20%) received at least 1 RBC transfusion. Ab screens were performed on all patients pre- and post-DARA therapy. Following drug administration, all patients showed a panagglutinin, and no patients formed new clinically significant alloantibodies. The turnaround time (TAT) and cost significantly decreased when the pretransfusion strategy with optimizing pretransfusion strategy.</p><p><strong>Conclusions: </strong>This is the most extensive study on patients treated with DARA and transfused, demonstrating no increased alloimmunization risk. DARA-related transfusion interference may be successfully mitigated by the novel strategy proposed here.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of the Veterans Affairs SeqFORCE (Sequencing for Research Clinical and Epidemiology) program for SARS-CoV-2 whole-genome sequencing.","authors":"Mark Holodniy, Ying Pei, Gary Stack, Christopher Wade, Yashpal Agrawal, Nicholas Barasch, Fady Baddoura, Carmen Kletecka, Patrick Adegboyega, Christina Trevino, Joel Mewton, Vafa Bayat, Anosh Mostaghimi, James S Klutts, Jessica Wang-Rodriguez","doi":"10.1093/ajcp/aqaf064","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf064","url":null,"abstract":"<p><strong>Objective: </strong>We sought to establish the US Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Sequencing for Research Clinical and Epidemiology (SeqFORCE) multilaboratory consortium for SARS-CoV-2 whole-genome sequencing (WGS).</p><p><strong>Methods: </strong>Clinical criteria were established for sending patient and employee samples from 145 VHA medical centers to 10 VHA clinical laboratories using 4 different WGS platforms. A linked pipeline among laboratories for SARS-CoV-2 clade and lineage interpretation, result transmission to electronic health records, and data storage was developed.</p><p><strong>Results: </strong>The SeqFORCE program went live on July 1, 2021. As of December 15, 2024, 51 307 samples have been analyzed by WGS for SARS-CoV-2. The median participant age was 60 years, 76.6% were male, and 13.5% were inpatients; 96.5% were Delta, Omicron, and Recombinant sublineages; and 78.5% represented SARS-CoV-2 postvaccination samples among patients and staff.</p><p><strong>Conclusions: </strong>Establishment of VA SeqFORCE enabled national population analysis for use in epidemiologic response and population health policy as well as expanded SARS-CoV-2 sequencing capacity to meet the demand for clinical and public health sequencing. The program consolidated operations using standardized procedures, test setup, analysis, reporting, and tracking. It also improved oversight and governance of VA contributions to global databases, mitigated system inefficiencies, and prepared VHA for future genomic challenges.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IRTA1 expression in extranodal marginal zone (MALT) lymphoma is variable across anatomic sites.","authors":"Narendra Bhattarai, James R Cook","doi":"10.1093/ajcp/aqaf056","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf056","url":null,"abstract":"<p><strong>Objective: </strong>Immune receptor translocation-associated 1 (IRTA1) expression, which has recently been shown to be highly specific for marginal zone lymphoma, is found in only a subset of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In this study, we examined whether IRTA1 expression in MALT lymphoma was dependent on anatomic location.</p><p><strong>Methods: </strong>IRTA1 immunohistochemistry was performed in 60 cases of extranodal MALT lymphoma, arising at breast, conjunctiva, lung, salivary gland, skin, and stomach (10 cases each). Expression was also scored with respect to detailed morphologic features.</p><p><strong>Results: </strong>IRTA1 staining was identified in 25 (42%) cases, ranging from 9 (90%) of 10 in lung to 2 (20%) of 10 in gastric MALT lymphoma. IRTA1 staining was not characteristic of specific morphologic features, as it was absent in most lymphoepithelial lesions, perifollicular cells, cells with overt monocytoid cytology, and plasmacytic cells. IRTA1 expression was also identified in 5 (50%) of 10 cases of pulmonary nodular lymphoid hyperplasia.</p><p><strong>Conclusions: </strong>IRTA1 expression is heterogeneous in extranodal MALT lymphoma. Staining for IRTA1 is not characteristic of specific morphologic features, but varies with the anatomic site of disease. Knowledge of site-specific differences in MALT lymphomas will facilitate diagnosis in routine clinical practice.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent or subsequent lymphomatous effusion in large B-cell lymphoma portends a dismal prognosis: A multi-institutional study.","authors":"Savanah D Gisriel, Ji Yuan, Haiming Tang, Jie Xu, Hong Fang, Shaoying Li, Jenna McCracken, Peng Li, Ryan C Braunberger, Zijun Y Xu-Monette, Xiaojun Wu, Endi Wang, Qian-Yun Zhang, Lorinda A Soma, Samuel G Katz, Jing Jing Zhang, Nana P Matsumoto, Ken H Young, Mina L Xu, Zenggang Pan","doi":"10.1093/ajcp/aqaf057","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf057","url":null,"abstract":"<p><strong>Objective: </strong>Rare large B-cell lymphomas (LBCLs) present with concurrent or subsequent lymphomatous effusion (solid-effusion LBCL, SE-LBCL), which may have an inferior prognosis compared with their noneffusion counterpart. In addition, the relationship between SE-LBCL and human herpesvirus 8-negative effusion-based LBCL (EB-LBCL) remains unclear.</p><p><strong>Methods: </strong>We collected 141 cases of SE-LBCL and a control cohort of 101 cases of stage IV solid-only LBCL. The clinicopathologic features were analyzed and compared between SE-LBCL and solid-only LBCL.</p><p><strong>Results: </strong>Patients with SE-LBCL had a median age of 67 years with a male-to-female ratio of 1.3:1. Eighty-six patients had concurrent solid lymphoma and lymphomatous effusion, whereas 55 developed lymphomatous effusion subsequently. Most cases involved the pleural cavities (79%, 112/141), followed by the peritoneal (21%, 29/141) and pericardial (11%, 16/141) cavities. BCL6, CD10, and MUM1 were expressed in 77% (90/117), 46% (60/130), and 61% (58/95) of cases, respectively, and 58% (71/123) were subclassified into the germinal center B-cell (GCB) subtype. Rearrangements of BCL2, BCL6, and MYC were detected in 42% (31/73), 35% (22/63), and 40% (35/88), respectively, and 22% (19/87) had both MYC and BCL2 rearrangements. The patients with SE-LBCL had a dismal prognosis, with a median survival of 5.7 months, which was significantly worse than solid-only LBCL (147.5 months; P < .0001).</p><p><strong>Conclusions: </strong>The pathologic features of SE-LBCL were similar to those of solid-only LBCL but distinct from those of EB-LBCL; in particular, lymphomatous effusion was an independently adverse prognostic factor in LBCL. Our study underscores the need for surveillance of lymphomatous effusion during LBCL staging and development of effective therapeutic regimens for SE-LBCL.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating molecular neuropathology of CNS neoplasms for the practicing surgical pathologist.","authors":"Brannon Broadfoot, Regina Kwon, Murat Gokden, Analiz Rodriguez, Kevin J Bielamowicz, Erika Santos Horta, J Stephen Nix","doi":"10.1093/ajcp/aqaf063","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf063","url":null,"abstract":"<p><strong>Objective: </strong>The practice of surgical neuropathology incorporates molecular results into diagnoses that already integrate histologic, radiologic, and clinical findings. Many surgical pathologists evaluate central nervous system (CNS) tumors without neuropathology board certification.</p><p><strong>Methods: </strong>This review describes key preanalytical, analytical, and postanalytical considerations for molecular testing and provides context for these considerations using frequently encountered CNS tumors. An overview of common molecular modalities, including limitations, is given, and pitfalls in interpretation are addressed.</p><p><strong>Conclusions: </strong>In summary, this review offers a practical reference for the diagnosis of CNS specimens in a general surgical pathology practice.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Roche Digital Pathology Dx whole slide imaging system is comparable to traditional microscopy for primary diagnosis in surgical pathology.","authors":"","doi":"10.1093/ajcp/aqaf076","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf076","url":null,"abstract":"","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}